Presented at AACR Annual Meeting 2024
Anne Bellon1,Omar Saavedra2, Ingrid M. E. Desar3, Mathilde Jalving4, Jourik A. Gietema4, Carla Van Herpen3, Stefan Van Ravensteijn3, Esteban Rodrigo Imedio1, Sylvia Van Haren1, Melanie Wirth1, Sandrine Micallef1, Vito Dozio1, Rikke Frederiksen Franzen1, Marie-Claude Roubaudi-Fraschini1, Valerie Nicolas-Metral1, Hans Gelderblom5.
1 Debiopharm International S.A., Lausanne, Switzerland
2 Vall d’Hebron University Hospital, Barcelona, Spain
3 Radboud University Medical Center, Nijmegen, Netherlands
4 University Medical Center Groningen (UMCG), Groningen, Netherlands
5 Leiden University Medical Center, Leiden, Netherlands
Background
Debio 0123, an oral brain-penetrant, highly selective WEE1 inhibitor, is currently in clinical development, both as monotherapy and in combination, for the treatment of patients with solid tumors. Food and gastric acid-reducing agents e.g. proton pump inhibitors (PPIs) may modify the solubility, bioavailability, safety and efficacy of oral cancer drugs. Polymedication in cancer patients is common and food restrictions can impact patient compliance and wellbeing. In order to adequately inform drug dosing in clinical trials, effects of food and high gastric pH on Debio 0123 bioavailability were studied over three cycles in patients participating in arm B of a dose escalation Phase 1 study in combination with carboplatin (CTID NCT03968653).